Lexicon Pharmaceuticals EBIT

The latest EBIT for LXRX is $-22M as of March 2026. That compares with $-170M in the prior-year period — up 87.2% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Lexicon Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, LXRX's EBIT moved from $-170M to $-22M — a 87.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lexicon Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, LXRX currently prints $-22M for EBIT, while the sector average sits near $23B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Lexicon Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-22M for LXRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting LXRX's EBIT ($-22M), review year-over-year change from $-170M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.